









Markets
/
Stocks
/
nasdaq-lnsr
/

LENSAR Inc

LNSR

12.080USD

-0.200-1.63%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

144.17MMarket Cap

LossP/E TTM



LENSAR Inc

12.080

-0.200-1.63%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LENSAR Inc

Currency: USD Updated: 2026-02-06

Key Insights

LENSAR Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 137 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LENSAR Inc's Score

Industry at a Glance

Industry Ranking

137 / 205

Overall Ranking

416 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

LENSAR Inc Highlights

StrengthsRisks

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 51.29% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.49M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 53.49M.

Fairly Valued

The company’s latest PE is -2.76, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.97M shares, decreasing 9.15% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 515.73K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.07.

Analyst Rating

Based on 0 analysts

Current Rating

15.000

Target Price

+22.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of LENSAR Inc is 6.56, ranking 147 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 14.32M, representing a year-over-year increase of 5.74%, while its net profit experienced a year-over-year increase of 147.20%.

Score

Industry at a Glance

Previous score

6.56

Change



Financials

4.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.53

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

LENSAR Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of LENSAR Inc is 6.73, ranking 154 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.76, which is -59.55% below the recent high of -1.12 and -124.02% above the recent low of -6.19.

Score

Industry at a Glance

Previous score

6.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for LENSAR Inc. The Healthcare Equipment & Supplies industry's average is 7.77. The average price target is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of LENSAR Inc is 6.94, ranking 72 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 12.85 and the support level at 11.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.17

Change

-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.102

Neutral

RSI(14)

49.287

Neutral

STOCH(KDJ)(9,3,3)

12.430

Sell

ATR(14)

0.353

High Vlolatility

CCI(14)

-88.988

Neutral

Williams %R

79.630

Sell

TRIX(12,20)

0.299

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

12.342

Sell

MA10

12.434

Sell

MA20

12.207

Sell

MA50

11.710

Buy

MA100

11.681

Buy

MA200

12.376

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of LENSAR Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 49.99%, representing a quarter-over-quarter increase of 5.96%. The largest institutional shareholder is Brandes Investmen, holding a total of 777.70K shares, representing 6.51% of shares outstanding, with 40.96% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

North Run Capital, LP

1.10M

Curtis (Nicholas T)

792.29K

Brandes Investment Partners, L.P.

Star Investors

777.70K

+37.99%

BlackRock Institutional Trust Company, N.A.

575.55K

+7.60%

Link (William J)

543.27K

-1.34%

The Vanguard Group, Inc.

Star Investors

507.60K

+0.29%

Connaughton (Alan B.)

279.22K

Lindstrom (Richard L)

239.04K

-2.99%

Dimensional Fund Advisors, L.P.

224.93K

Geode Capital Management, L.L.C.

217.89K

-0.68%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LENSAR Inc is 4.05, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. LENSAR Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.